Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

OP believes RU58841 affected their thyroid, causing hypothyroidism and impacting minoxidil's effectiveness. They plan to start thyroid medication to improve hair regrowth.

Kintor Pharma has started a Phase II trial in China for GT20029, a potential new treatment for hair loss. Participants are discussing the significance, potential release dates, and comparing it to other treatments and technologies like stem cell hair transplants and SAMIRNA.

Federal funding cuts have delayed PP405 research, affecting hair loss treatment progress, though clinical trials will continue. The discussion highlights PP405's potential compared to minoxidil and finasteride and stresses the importance of government-funded research.

Kintor Pharma completed patient enrollment for a Phase II trial in China for GT20029, a potential new treatment for hair loss. Some believe GT20029 could replace finasteride if effective, while others discuss finasteride's limited efficacy and potential underreported side effects.

The conversation discusses using different concentrations of topical treatments for hair loss, specifically Minoxidil, Finasteride, Dutasteride, and Tretinoin. The user is considering higher concentrations after previous treatments were ineffective.

The conversation provides a detailed list of blood tests recommended before starting finasteride to establish a baseline for monitoring potential side effects. A shorter list is also provided for those with limited funds, and the user shares personal experience of using finasteride without issues for about nine years.

The user shared their experience with hair loss treatments, including low-dose minoxidil, finasteride, and essential oils, and expressed concerns about the cognitive side effects of finasteride. They are seeking more information on how finasteride may affect cognition and are considering whether to continue or stop the treatment.

There are no tests to determine genetic follicle sensitivity for hair loss, and conclusions are based on hypothetical or post-balding observations. Finasteride is mentioned as an easy, consistent treatment option compared to natural treatments.

OP experienced side effects from finasteride and is considering using RU58841 to prevent hair loss during a testosterone cycle. They have also used minoxidil, Nizoral, alfatradiol, and fluridil successfully.

The user is seeking alternatives to propylene glycol and glycerin for mixing with RU58841 due to allergies and greasiness. Suggestions include reducing glycerin and considering stemoxydine as a solvent.

Hair loss treatments discussed include Dutasteride with Ketoconazole, tissue engineering strategies, and androgenetic alopecia therapies. Massage doubles follicular retention, improving treatment effectiveness.

The conversation discusses alternative and unorthodox hair loss treatments, including RU58841, nandrolone, and dianabol, as well as theoretical approaches involving high doses of estrogen and selective estrogen receptor modulators. These methods are considered extreme and potentially harmful but are explored for those unable to tolerate traditional 5-alpha reductase inhibitors.

The conversation discusses a personal theory on the role of DHT in stress and reproduction, suggesting it converts testosterone for reproductive traits. The discussion includes skepticism and mentions individual differences in physiology and neurochemistry.

Caffeine intake may increase DHT levels, but its impact on hair loss is minimal compared to genetic factors. Excessive caffeine can cause health issues, and its effects on hair loss are not directly applicable to humans based on rat studies.

Minoxidil is highly toxic to cats and can cause fatal heart issues. Users recommend switching to oral minoxidil to protect pets.

The user stopped finasteride for family planning but plans to restart it and is considering dutasteride. Users discuss the safety of finasteride during family planning, with some sharing experiences of having healthy children while on the medication.

The FDA warned that topical finasteride can cause serious side effects like sexual dysfunction and brain fog, similar to oral finasteride. Compounded topical formulations pose additional risks due to lack of regulation.

The user is experiencing an allergic reaction to propylene glycol in Kirkland minoxidil and is considering switching to a foam version or a low-PG minoxidil solution. They are also contemplating oral minoxidil but are concerned about its long-term safety.

The user is concerned about high prolactin levels and low testosterone levels after stopping finasteride for three weeks. They are considering resuming finasteride but are worried it might further increase prolactin levels.

PP405 is a topical gel being tested for hair regrowth in adults with androgenetic alopecia. Volunteers aged 18-55 are needed for a 16-week trial in several US locations.

Minoxidil is highly toxic to cats and can be fatal with minimal exposure. Users suggest switching to oral minoxidil or taking precautions to prevent pet exposure.

The user has been taking 0.5 finasteride for 10 months and wants to repeat blood tests, including estradiol. However, their doctor is reluctant to test estradiol, arguing it's typically low in men, and the user is considering seeking a second opinion.

Treatments for hair loss, such as minoxidil, finasteride, and RU58841; humorous posts about hair loss; and the choice to stop using treatments in exchange for a different look.

The conversation is about a user seeking information on a clinical trial by Amplifica - Scube3 for Androgenetic Alopecia (AGA). The user is unsure if it's a formal phase 1 study.

Topical finasteride is not known to be toxic to cats like minoxidil, but careful handling is advised to prevent ingestion or skin contact. OP seeks reassurance to convince their girlfriend of its safety around their cat.

Dr. Toyos is recruiting more participants for a larger trial on hair loss treatments. The discussion mentions Minoxidil, finasteride, and RU58841 as potential treatments.

GT20029 and KX826 are promising hair loss treatments, with GT20029 increasing hair count and KX826 showing significant results. KX826 may be a good alternative for those who can't use finasteride or dutasteride, though results vary.

The conversation humorously discusses a visit to the Everychem laboratory, with a focus on hair loss treatments like Minoxidil, finasteride, and RU58841. The tone is satirical.

The conversation is about the potential availability of GT20029 on the black market and whether users would try it. Participants advise waiting for phase 3 trial results to ensure safety and efficacy.

PTD-DBM therapy for hair loss is being developed by Dr. Kang-Yell Choi, with human testing planned in South Korea. Some clinics in the U.S. offer PTD-DBM/valproic acid therapy, but it hasn't completed trials yet.